In addition, patients with high IFN-γ/IMS ratios (using the Youden index to determine the cutoff point) had better ORR on the VanAllen15 dataset (p = 0.0004; Supplementary Fig. 4E) and the Kim18 dataset (p = 0.0022; Supplementary Fig. 4F) and longer OS in the VanAllen15 dataset (HR = 3.06; 95% CI: 1.41–6.61; p = 0.0032; Fig. 6H) than patients with low IFN-γ/IMS ratios, suggesting the potential of using the IFN-γ/IMS ratio as a predictive biomarker for immunotherapies different to anti-PD-1, or other cancer types. This evidence concerns the gene IFNG and cancer.